These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 33642438)

  • 1. [Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia].
    Iida K; Yano T; Ikemori M; Ishida T; Nishimura N
    Yakugaku Zasshi; 2021 Jun; 141(6):877-886. PubMed ID: 33642438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Consideration on Academia Environments for Creating Medical Innovation].
    Iida K; Ishida T; Nishimura N
    Yakugaku Zasshi; 2022 Jan; 142(1):75-84. PubMed ID: 34629350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Academia-pharma partnerships for novel drug discovery: essential or nice to have?
    Palmer M; Chaguturu R
    Expert Opin Drug Discov; 2017 Jun; 12(6):537-540. PubMed ID: 28394189
    [No Abstract]   [Full Text] [Related]  

  • 4. The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.
    Takebe T; Imai R; Ono S
    Clin Transl Sci; 2018 Nov; 11(6):597-606. PubMed ID: 29940695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strengthening the Competitiveness of Japan's Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan's Highly Productive Firm.
    Okuyama R
    Biol Pharm Bull; 2023; 46(5):718-724. PubMed ID: 37121698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Open innovation: public-private partnerships in pharmaceutical R&D].
    Uchibayashi N
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):32-8. PubMed ID: 23842226
    [No Abstract]   [Full Text] [Related]  

  • 8. Discovery of PET radiopharmaceuticals at the academia-industry interface.
    Bernard-Gauthier V; Collier TL; Liang SH; Vasdev N
    Drug Discov Today Technol; 2017 Nov; 25():19-26. PubMed ID: 29233263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expectation for the drug development activity in academia].
    Inagaki O
    Yakugaku Zasshi; 2013; 133(2):213-9. PubMed ID: 23370516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partners in discovery.
    Fuyuno I
    Nature; 2018 Mar; 555(7697):S60. PubMed ID: 29565400
    [No Abstract]   [Full Text] [Related]  

  • 11. Toward the development of a vibrant, super-aged society: The future of medicine and society in Japan.
    Iijima K; Arai H; Akishita M; Endo T; Ogasawara K; Kashihara N; Hayashi YK; Yumura W; Yokode M; Ouchi Y
    Geriatr Gerontol Int; 2021 Aug; 21(8):601-613. PubMed ID: 34212470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Academic-Pharma drug discovery alliances: seeking ways to eliminate the valley of death.
    Hammonds T
    Future Med Chem; 2015; 7(14):1891-9. PubMed ID: 26393391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The path to producing pharmaceuticals from natural products uncovered by academia-from the perspective of a science coordinator.
    Fujie A
    Biosci Biotechnol Biochem; 2017 Jan; 81(1):38-42. PubMed ID: 27885934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.
    Chung TD
    Comb Chem High Throughput Screen; 2014 Mar; 17(3):272-89. PubMed ID: 24409951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective.
    Germann PG; Schuhmacher A; Harrison J; Law R; Haug K; Wong G
    Hum Genomics; 2013 Mar; 7(1):5. PubMed ID: 23496921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orphan diseases: state of the drug discovery art.
    Volmar CH; Wahlestedt C; Brothers SP
    Wien Med Wochenschr; 2017 Jun; 167(9-10):197-204. PubMed ID: 26819216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health.
    D'Hooghe T
    Hum Reprod; 2017 Aug; 32(8):1549-1555. PubMed ID: 28854594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry.
    Litten RZ; Ryan M; Falk D; Fertig J
    Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.